abrdn plc Sells 75,879 Shares of Akero Therapeutics, Inc. (NASDAQ:AKRO)

abrdn plc cut its stake in shares of Akero Therapeutics, Inc. (NASDAQ:AKRO) by 38.1% during the 3rd quarter, Holdings Channel.com reports. The fund owned 123,358 shares of the company’s stock after selling 75,879 shares during the period. abrdn plc’s holdings in Akero Therapeutics were worth $3,539,000 as of its most recent SEC filing.

Several other large investors have also bought and sold shares of AKRO. Mirae Asset Global Investments Co. Ltd. raised its holdings in shares of Akero Therapeutics by 21.6% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,511 shares of the company’s stock valued at $71,000 after purchasing an additional 446 shares during the last quarter. Ameritas Investment Partners Inc. lifted its position in shares of Akero Therapeutics by 20.0% during the 1st quarter. Ameritas Investment Partners Inc. now owns 6,175 shares of the company’s stock worth $156,000 after buying an additional 1,030 shares in the last quarter. Russell Investments Group Ltd. increased its position in shares of Akero Therapeutics by 2,366.0% during the first quarter. Russell Investments Group Ltd. now owns 1,233 shares of the company’s stock valued at $31,000 after acquiring an additional 1,183 shares during the last quarter. Principal Financial Group Inc. grew its position in Akero Therapeutics by 15.6% during the first quarter. Principal Financial Group Inc. now owns 13,766 shares of the company’s stock valued at $348,000 after buying an additional 1,858 shares during the period. Finally, Handelsbanken Fonder AB increased its holdings in Akero Therapeutics by 12.4% during the third quarter. Handelsbanken Fonder AB now owns 20,000 shares of the company’s stock worth $574,000 after buying an additional 2,200 shares during the last quarter.

Insider Buying and Selling at Akero Therapeutics

In other news, insider Catriona Yale sold 5,200 shares of the firm’s stock in a transaction on Monday, August 26th. The stock was sold at an average price of $27.51, for a total value of $143,052.00. Following the completion of the transaction, the insider now directly owns 75,931 shares of the company’s stock, valued at $2,088,861.81. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. In other news, insider Catriona Yale sold 5,200 shares of the firm’s stock in a transaction that occurred on Monday, August 26th. The shares were sold at an average price of $27.51, for a total value of $143,052.00. Following the completion of the transaction, the insider now directly owns 75,931 shares in the company, valued at approximately $2,088,861.81. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Andrew Cheng sold 63,539 shares of the company’s stock in a transaction on Friday, October 18th. The stock was sold at an average price of $31.53, for a total transaction of $2,003,384.67. Following the completion of the transaction, the chief executive officer now directly owns 605,417 shares in the company, valued at approximately $19,088,798.01. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 269,315 shares of company stock valued at $7,958,413 in the last 90 days. 7.94% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reissued a “buy” rating and set a $50.00 target price on shares of Akero Therapeutics in a research report on Tuesday, September 17th. One investment analyst has rated the stock with a hold rating and six have given a buy rating to the stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $43.20.

Akero Therapeutics Trading Up 4.9 %

Shares of Akero Therapeutics stock opened at $32.33 on Monday. The stock has a market capitalization of $2.24 billion, a P/E ratio of -9.48 and a beta of -0.26. Akero Therapeutics, Inc. has a 52-week low of $12.96 and a 52-week high of $37.00. The company has a debt-to-equity ratio of 0.04, a quick ratio of 24.89 and a current ratio of 24.89. The stock’s 50-day simple moving average is $28.32 and its 200 day simple moving average is $24.81.

Akero Therapeutics (NASDAQ:AKRO) last posted its quarterly earnings results on Friday, August 9th. The company reported ($0.81) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.90) by $0.09. As a group, research analysts anticipate that Akero Therapeutics, Inc. will post -3.64 EPS for the current year.

Akero Therapeutics Profile

Akero Therapeutics, Inc, together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients.